{
  "source": "PA-Notification-Orserdu.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1407-3\nProgram Prior Authorization/Notification\nMedication Orserdu™ (elacestrant)\nP&T Approval Date 3/2023, 3/2024, 3/2025\nEffective Date 6/1/2025\n1. Background:\nOrserdu (elacestrant) is an estrogen receptor antagonist indicated for treatment of postmenopausal\nwomen or adult men, with estrogen receptor (ER)-positive, human epidermal growth factor\nreceptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer with disease\nprogression following at least one line of endocrine therapy. NCCN also recommends for\npremenopausal women treated with ovarian ablation/suppression.\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age of\n19 years, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or\nunder some circumstances. Some states also mandate usage of other Compendium references.\nWhere such mandates apply, they supersede language in the benefit document or in the notification\ncriteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Orserdu will be approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Breast Cancer\n1. Initial Authorization\na. Orserdu will be approved based on all of the following criteria:\n(1) Diagnosis of breast cancer\n-AND-\n(2) One of the following:\n(a) Advanced\n(b) Metastatic\n© 2025 UnitedHealthcare Services, Inc.\n1\n-AND-\n(3) Disease is estrogen receptor (ER)-positive\n-AND-\n(4) Disease is human epidermal growth factor receptor 2 (HER2)-negative\n-AND-\n(5) Presence of an ESR1 gene mutation\n-AND-\n(6) Patient is one of the following:\n(a) Postmenopausal woman\n(b) Male\n(c) Premenopausal woman treated with ovarian ablation/suppression\n-AND-\n(7) Disease has progressed following at least one line of endocrine therapy",
    " of the following:\n(a) Postmenopausal woman\n(b) Male\n(c) Premenopausal woman treated with ovarian ablation/suppression\n-AND-\n(7) Disease has progressed following at least one line of endocrine therapy\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Orserdu will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Orserdu therapy.\nAuthorization will be issued for 12 months.\nC. NCCN Recommended Regimens\n1. The drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a\nCategory of Evidence and Consensus of 1, 2A, or 2B\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n© 2025 UnitedHealthcare Services, Inc.\n2\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Orserdu [package insert]. New York, NY: Stemline Therapeutics, Inc.; November 2023.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium®). Available at\nwww.nccn.org. Accessed February 7, 2025.\nProgram Prior Authorization/Notification – Orserdu (elacestrant)\nChange Control\n3/2023 New program.\n3/2024 Annual review. Added premenopausal women treated with ovarian\nablation/suppression to coverage criteria per NCCN. Updated\nbackground and references.\n3/2025 Annual review with no changes to coverage criteria.\n© 2025 UnitedHealthcare Services, Inc.\n3"
  ]
}